⚠️ Teaching Case Note: This case has been de-identified and reconstructed for educational purposes. Clinical details reflect real surgical decision-making and outcomes. Patient identity is fully protected.
Creatinine 680, 40% Crescents, Dialysis Predicted Within Months — Kidney Function Partially Recovered, Dialysis Avoided
He was 32 years old, French, working in Shanghai. Two weeks of blood in his urine and foamy urine. Three days after a blood test showed his creatinine at 680 μmol/L — more than six times the upper limit of normal, with an eGFR of 12 mL/min — he was sitting in the nephrology clinic at Ruijin Hospital. His blood pressure was 160/100. His legs were swollen. His 24-hour urine protein was 3.8 grams.
The kidney biopsy confirmed the worst-case scenario within the IgA nephropathy spectrum: crescentic IgA nephropathy, Lee Grade V, with cellular and fibrocellular crescents in 40% of glomeruli and tubular atrophy already present in more than 25% of the cortex. Without aggressive treatment, the probability of reaching end-stage renal disease requiring dialysis within three to six months was above 80%.
Dr. Nan Chen's team at Ruijin Hospital initiated pulse corticosteroid therapy combined with mycophenolate mofetil (MMF). The treatment carried significant infection risk in a patient with a creatinine of 680. The alternative was certain dialysis.
At six months, creatinine had fallen to 210 μmol/L. Proteinuria had reduced to 0.8 g/day. Dialysis had been avoided. The patient had returned to work.
The Biopsy: Why Pathology Is the Entire Diagnosis in Glomerular Disease
The clinical presentation — gross hematuria, nephrotic-range proteinuria, rapidly rising creatinine, elevated serum IgA, and a preceding upper respiratory infection — was consistent with IgA nephropathy. But IgA nephropathy is not one disease. It is a spectrum ranging from mild mesangial deposits with minimal clinical consequence to crescentic glomerulonephritis with a trajectory indistinguishable from ANCA-associated vasculitis. The treatment and prognosis differ completely across this spectrum. The biopsy is not confirmatory — it is the diagnosis.
The Oxford MEST-C classification defined the pathological risk profile precisely. Mesangial hypercellularity (M1) and endocapillary proliferation (E1) indicated active inflammatory injury — potentially reversible with immunosuppression. Segmental glomerulosclerosis (S1) indicated established scarring in a subset of glomeruli. Tubular atrophy and interstitial fibrosis exceeding 25% of the cortex (T1) indicated that chronic, irreversible injury had already occurred — a finding that tempers the expected response to treatment and informs the long-term prognosis.
The critical finding was the crescent score: cellular and fibrocellular crescents in 40% of glomeruli (C classification, high). Crescents represent parietal epithelial cell proliferation in response to glomerular rupture — a marker of the most severe acute glomerular injury. Cellular crescents are potentially reversible; fibrocellular crescents are partially organized and less responsive to treatment. The 40% crescent burden, combined with the T1 tubular atrophy, defined a patient at the intersection of salvageable acute injury and established chronic damage — where the window for intervention was narrow and closing.
Complement levels (C3 and C4 normal) excluded lupus nephritis and membranoproliferative glomerulonephritis. ANCA was negative. The diagnosis was primary IgA nephropathy, crescentic variant, Lee Grade V.
The MDT Decision: Aggressive Immunosuppression Despite the Infection Risk
The nephrology team's discussion centered on a risk-benefit calculation that is specific to crescentic glomerulonephritis: the risk of immunosuppression in a patient with severely impaired renal function versus the near-certainty of dialysis dependence without it.
At a creatinine of 680 μmol/L, the immune system is already dysregulated by uremia. High-dose corticosteroids and cytotoxic agents in this context carry elevated risks of bacterial infection, opportunistic infection, and impaired wound healing. These risks are real and must be managed actively. But the alternative — conservative management without immunosuppression — in a patient with 40% crescents and a creatinine rising from a baseline that was likely normal two weeks earlier, is not a safe choice. It is a choice to accept dialysis.
Dr. Chen's team selected methylprednisolone pulse therapy (intravenous, three consecutive days) followed by oral prednisolone, combined with mycophenolate mofetil (MMF) rather than cyclophosphamide. The rationale for MMF over cyclophosphamide in this case was the patient's age (32 years, with fertility considerations), the absence of ANCA positivity (which would have strengthened the case for cyclophosphamide), and the MMF's more favorable infection profile at equivalent immunosuppressive potency for IgA nephropathy specifically.
Prophylactic trimethoprim-sulfamethoxazole was prescribed for Pneumocystis jirovecii pneumonia prevention. Proton pump inhibitor cover was initiated. Blood pressure was controlled with an ACE inhibitor — providing both antihypertensive and antiproteinuric effect through renin-angiotensin system blockade. Dietary sodium and protein restriction were implemented. The patient was counseled on infection surveillance and instructed to present immediately with any fever.
Treatment Course and Response
Weeks 1–2 — pulse therapy. Methylprednisolone 500 mg intravenously daily for three days, then transition to oral prednisolone 1 mg/kg/day. MMF initiated at 1.0 g twice daily. Blood pressure controlled to below 130/80 mmHg within five days on ACE inhibitor and amlodipine. Gross hematuria resolved by day seven. Creatinine stabilized — the rate of rise halted, which in crescentic nephritis is itself a meaningful early response signal.
Month 1. Creatinine had fallen from 680 to 420 μmol/L — a 38% reduction, confirming that a significant component of the renal impairment was acute and reversible. Proteinuria reduced to 2.1 g/day. No infectious complications. Prednisolone tapering begun at week four per protocol.
Month 3. Creatinine 280 μmol/L. Proteinuria 1.2 g/day. Blood pressure controlled on single agent. The patient had returned to part-time work. Prednisolone tapered to 20 mg/day. MMF continued at full dose.
Month 6. Creatinine 210 μmol/L. Proteinuria 0.8 g/day — below the 1 g threshold that defines high-risk for progressive CKD. eGFR had recovered from 12 to 31 mL/min — from near-dialysis to CKD Stage 3b. The patient was working full-time, exercising moderately, and managing his blood pressure with a single medication. Prednisolone tapered to 10 mg/day; MMF continued for planned 18-month total course.
Expert Commentary — Dr. Nan Chen
"Crescentic IgA nephropathy is one of the few true emergencies in nephrology — not because the patient is immediately life-threatened, but because the window for renal salvage is measured in weeks, not months. Every week of delay in diagnosis and treatment allows more crescents to organize from cellular to fibrocellular to fibrous — and fibrous crescents do not respond to immunosuppression. The biopsy in this case was performed within 48 hours of presentation. That timing is not incidental. It is the treatment.
The decision to use MMF rather than cyclophosphamide reflects the evolution of evidence in IgA nephropathy management over the past decade. Cyclophosphamide remains appropriate for ANCA-associated crescentic nephritis, where the evidence base is strongest. For IgA nephropathy specifically, MMF has demonstrated comparable efficacy in the crescentic variant with a more acceptable toxicity profile — particularly relevant for a 32-year-old patient where gonadotoxicity is a meaningful consideration.
The T1 tubular atrophy finding on biopsy is the honest part of this case. It tells us that some of the renal damage was already chronic and irreversible at the time of presentation — that the creatinine will not return to normal, and that this patient will require lifelong nephrology follow-up and cardiovascular risk management. The goal of treatment was not cure. It was to stop the acute crescentic injury, preserve the remaining functional nephrons, and keep the patient off dialysis. At six months, creatinine is 210 and eGFR is 31. That is a meaningful outcome. It is not a complete one.
For international patients in Shanghai, the critical advantage of early specialist access is the biopsy. In many healthcare systems, a 32-year-old with hematuria and a creatinine of 680 would wait weeks for a nephrology appointment and further weeks for a biopsy. In this case, the biopsy was performed within 48 hours of the first nephrology consultation. That speed is what made the treatment possible."
About Dr. Nan Chen
Dr. Nan Chen is Chief of Nephrology at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, and one of China's leading experts in chronic kidney disease, IgA nephropathy, and renal replacement therapy. He has spearheaded national guidelines for CKD management and is highly experienced in treating international patients with complex glomerular diseases. Dr. Chen's department is among the highest-volume nephrology units in East China, with particular expertise in rapidly progressive glomerulonephritis, lupus nephritis, and membranous nephropathy.
How CMCS Supported This Patient
China Medical Concierge – Shanghai (CMCS) coordinated the full care pathway for this French patient: urgent specialist matching and same-day nephrology consultation at Ruijin Hospital, coordination of the emergency renal biopsy within 48 hours of presentation — including pre-biopsy coagulation workup, ultrasound guidance scheduling, and post-biopsy monitoring — French and English interpretation for all consultations including the detailed informed consent discussion for immunosuppressive therapy in a patient with severely impaired renal function, family communication support with the patient's family in France, international insurance documentation and coordination, and long-term follow-up planning including liaison with the patient's nephrologist in France for shared care management of his CKD Stage 3b on return to Europe.
For international patients and expatriates in Shanghai facing acute kidney emergencies — where the speed of specialist access, biopsy timing, and immunosuppression decision-making determines whether renal function is preserved or lost permanently — CMCS provides end-to-end support from emergency triage to long-term international care coordination.
📧 contract@medicalsh.com | 📱 WhatsApp | 🌐 medicalsh.com
0 commenti